23andMe announced that it is working with Celmatix on a new fertility study. The purpose of the study is to answer one question. How does DNA impact a woman’s reproductive health and ability to conceive?
Celmatix is a personalized medicine company focused on fertility and women’s health. Their technology-enabled produces empower people, through better data, to dramatically improve their chances of conceiving. 23andMe and Celmatix have together launched a Fertility Research Community that will use genetic and other data to uncover more on what impacts a woman’s ability to conceive.
Celmatix and 23andMe believe genetic information could help women, with their doctors, understand their potential to get pregnant, carry a pregnancy to term and identify their treatment options if needed. To get there, 23andMe and Celmatix need to learn more. The answer given by women who participate in the study, along with the women’s DNA samples, can help researchers understand how fertility differences are expressed in our genes.
Right now, many of the causes of infertility are unknown, but previous research suggests that there may be a strong genetic component involved. The 23andMe online-based platform enables a large group of individuals to come together to provide valuable data to researchers.
Those who want to participate in the study must meet the following qualifications:
* You are female, 18-45, have access to the internet and live in the United States.
* One of the following circumstances applies to you: you think you may become pregnant within the next 6 months; you are actively trying to conceive; you are pregnant; you have been pregnant in the last 12 months.
* You have a male partner with whom you are trying to conceive using no medical assistance.
* Your male partner has given you permission to answer survey questions about his health history.
* Your male partner has not had a vasectomy, testicular surgery/infection, or erectile/ejaculatory disfunction. He cannot have been diagnosed with any condition known to cause infertility or be taking medications known to adversely impact male fertility.
* You have not had your ovaries, uterus or fallopian tubes surgically removed, tied, or operated on.
* Neither you, nor your partner, has undergone chemotherapy and/or radiation therapy.
Those who participate in this research study will receive complimentary access to 23andMe’s Personal Genetic Service. With the Health + Ancestry Service, a participant can receive over 65 personalized reports on their health, traits, and ancestry. Participants will continue to have access to their 23andMe account (and receive report updates) as long as the genetic information in those updates is from their original DNA sample.
Related Articles at FamilyTree.com:< Return To Blog